Robeauté raises $28m to advance neurosurgical microbots

The new funding will be used to continue developing the technology, starting human trials in 2026 and setting up US operations ahead of FDA approval and commercialisation. 

Robeauté, a French medtech company, said neurological disorders are difficult to diagnose in the early stages when intervention can have the most impact. Modern neurosurgery relies on relatively crude methods, with stiff tools pushed through the brain in a straight line, impeding multi-site access and precise targeting. Pharmaceutical treatments struggle to make an impact due to the complexities of crossing the blood-brain barrier to reach the site of interest.

MORE FROM MEDICAL & HEALTHCARE

The size of a grain of rice, Robeauté’s microrobots can move along curved routes through the extracellular matrix to safely reach multiple sites of interest and carry out whichever task is required.

According to the company, the modular medical devices can embark on specific missions depending on the pathology, making them suited delivering molecules, implanting an electrode and collecting cell or live-data samples through sensors to transform the understanding and ability to treat neuropathologies.